Target haematocrit during erythropoietin therapy.
Nissenson
A R
AR
Besarab
A
A
Bolton
W K
WK
Goodkin
D A
DA
Schwab
S J
SJ
D002319:Cardiovascular System / Q000503:physiopathology; D002408:Catheters, Indwelling / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D010807:Physical Endurance; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D011994:Recombinant Proteins; D004921:Erythropoietin